10x Genomics Stock Buy Hold or Sell Recommendation
| TXG Stock | USD 10.34 0.46 4.66% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding 10X Genomics is 'Cautious Hold'. Macroaxis provides 10X Genomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TXG positions.
Check out 10X Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide. Note, we conduct extensive research on individual companies such as 10X and provide practical buy, sell, or hold advice based on investors' constraints. 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
10X |
Execute 10X Genomics Buy or Sell Advice
The 10X recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on 10X Genomics. Macroaxis does not own or have any residual interests in 10X Genomics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute 10X Genomics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
10X Genomics Trading Alerts and Improvement Suggestions
| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 414.78 M. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 2 Reasons to Sell TXG and 1 Stock to Buy Instead |
10X Genomics Returns Distribution Density
The distribution of 10X Genomics' historical returns is an attempt to chart the uncertainty of 10X Genomics' future price movements. The chart of the probability distribution of 10X Genomics daily returns describes the distribution of returns around its average expected value. We use 10X Genomics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of 10X Genomics returns is essential to provide solid investment advice for 10X Genomics.
| Mean Return | -0.55 | Value At Risk | -8.83 | Potential Upside | 5.49 | Standard Deviation | 4.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of 10X Genomics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
10X Stock Institutional Investors
| Shares | Brown Capital Management, Llc | 2024-12-31 | 1.8 M | Assenagon Asset Management Sa | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.8 M | State Street Corp | 2024-12-31 | 1.8 M | Voloridge Investment Management, Llc | 2024-12-31 | 1.6 M | Deerfield Management Co | 2024-12-31 | 1.5 M | Two Sigma Investments Llc | 2024-12-31 | 1.3 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.2 M | Fmr Inc | 2024-12-31 | 13.5 M | Ark Investment Management Llc | 2024-12-31 | 11.9 M |
10X Genomics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (14.6M) | (30.1M) | (21.2M) | 7.9M | (9.8M) | (10.3M) | |
| Investments | (38.4M) | (106.7M) | (350.9M) | 87.2M | (32.6M) | (34.3M) | |
| Change In Cash | 212.2M | (92.6M) | (368.7M) | 131.9M | (15.2M) | (14.5M) | |
| Free Cash Flow | (256.3M) | (122.7M) | (165.3M) | (64.7M) | (5.7M) | (6.0M) | |
| Depreciation | 19.0M | 28.3M | 33.0M | 43.6M | 43.7M | 25.1M | |
| Other Non Cash Items | 306.0M | 79K | 2.0M | 12.0M | 3.6M | 3.4M | |
| Capital Expenditures | 38.4M | 101.3M | 131.7M | 49.5M | 12.4M | 11.8M | |
| Net Income | (542.7M) | (58.2M) | (166M) | (255.1M) | (182.6M) | (191.8M) | |
| End Period Cash Flow | 688.6M | 596.1M | 227.4M | 359.3M | 344.1M | 386.4M | |
| Change To Netincome | 13.9M | 356.2M | 96.0M | 137.9M | 158.6M | 111.7M |
10X Genomics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to 10X Genomics or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that 10X Genomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a 10X stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.41 | |
β | Beta against Dow Jones | 1.35 | |
σ | Overall volatility | 4.36 | |
Ir | Information ratio | -0.1 |
10X Genomics Volatility Alert
10X Genomics exhibits very low volatility with skewness of -0.71 and kurtosis of 1.53. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure 10X Genomics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact 10X Genomics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.10X Genomics Fundamentals Vs Peers
Comparing 10X Genomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze 10X Genomics' direct or indirect competition across all of the common fundamentals between 10X Genomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as 10X Genomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of 10X Genomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing 10X Genomics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare 10X Genomics to competition |
| Fundamentals | 10X Genomics | Peer Average |
| Return On Equity | -0.25 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Profit Margin | (0.30) % | (1.27) % |
| Operating Margin | (0.30) % | (5.51) % |
| Current Valuation | 897.55 M | 16.62 B |
| Shares Outstanding | 108.25 M | 571.82 M |
| Shares Owned By Insiders | 2.13 % | 10.09 % |
| Shares Owned By Institutions | 96.90 % | 39.21 % |
| Number Of Shares Shorted | 11.32 M | 4.71 M |
| Price To Book | 1.70 X | 9.51 X |
| Price To Sales | 2.07 X | 11.42 X |
| Revenue | 610.78 M | 9.43 B |
| Gross Profit | 414.78 M | 27.38 B |
| EBITDA | (133.99 M) | 3.9 B |
| Net Income | (182.63 M) | 570.98 M |
| Cash And Equivalents | 499.73 M | 2.7 B |
| Cash Per Share | 4.39 X | 5.01 X |
| Total Debt | 82.61 M | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 5.65 X | 2.16 X |
| Book Value Per Share | 5.81 X | 1.93 K |
| Cash Flow From Operations | 6.66 M | 971.22 M |
| Short Ratio | 4.44 X | 4.00 X |
| Earnings Per Share | (1.52) X | 3.12 X |
| Price To Earnings To Growth | 0.13 X | 4.89 X |
| Target Price | 16.0 | |
| Number Of Employees | 1.31 K | 18.84 K |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 1.26 B | 19.03 B |
| Total Asset | 918.64 M | 29.47 B |
| Retained Earnings | (1.47 B) | 9.33 B |
| Working Capital | 466.75 M | 1.48 B |
| Net Asset | 918.64 M |
Note: Disposition of 1700 shares by Serge Saxonov of 10X Genomics at 55.1465 subject to Rule 16b-3 [view details]
10X Genomics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as 10X . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About 10X Genomics Buy or Sell Advice
When is the right time to buy or sell 10X Genomics? Buying financial instruments such as 10X Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having 10X Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Supplies Thematic Idea Now
Business Supplies
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Check out 10X Genomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.